Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

AstraZeneca Receives European Approval for VIMOVO

By Pharmaceutical Processing | October 11, 2010

AstraZeneca and POZEN Inc. today announced that VIMOVO (naproxen/
esomeprazole magnesium) 500/20 mg modified-release tablets has cleared
an important regulatory milestone by receiving positive agreement for
approval in 23 countries across the European Union (EU). This follows
all 22 Concerned Member States agreeing with the assessment of the
Netherlands Health Authority (MEB), acting as the Reference Member State
for the Decentralised Procedure (DCP).  It also results in a harmonised
Summary of Product Characteristics (SmPC). The Member States will now
pursue pricing and reimbursement and national approvals.

 

VIMOVO
is indicated for the symptomatic treatment of osteoarthritis (OA),
rheumatoid arthritis (RA), and ankylosing spondylitis (AS) in patients
who are at risk for developing non-steroidal anti-inflammatory drug
(NSAID)-associated gastric and/or duodenal ulcers and where treatment
with lower doses of naproxen or of other NSAIDs is not considered
sufficient.

 

VIMOVO, co-developed by AstraZeneca and POZEN Inc., is
a fixed-dose combination of enteric-coated naproxen, a pain-relieving
NSAID, and immediate-release esomeprazole, a proton pump inhibitor
(PPI). The positive agreement is based on a submission package including
data from the pivotal trials PN400-301 and PN400-302, which
demonstrated that patients taking VIMOVO experienced significantly fewer
endoscopic gastric ulcers, compared to patients receiving
enteric-coated naproxen.

 

“This support for the approval of VIMOVO
in Europe is a significant milestone, which we believe will provide a
new treatment option for the millions of arthritis patients in the EU at
risk for NSAID-associated ulcers,” said Lori Kreamer, Global Products
Vice President, AstraZeneca. “In one tablet, VIMOVO offers the proven
pain relief of naproxen with built-in ulcer risk reduction.” 

Nearly
151 million people worldwide and approximately 28 million people in
Europe suffer from OA, which is the most common form of arthritis. 
While many patients with OA treat their symptoms with NSAIDs, 50% of
chronic NSAID users are at risk of gastrointestinal ulcers.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE